Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
NCT01173523
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
STA-9090
Sponsor
David M. Jackman, MD
Collaborators
[object Object]
[object Object]
[object Object]